BSX
Boston Scientific Corporation
$56.91
-$0.70(-1.22%)
50
Overall
45
Value
36
Tech
71
Quality
Market Cap
$86.87B
Volume
10.03M
52W Range
$59.39 - $109.50
Target Price
$90.83
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $8.4B | $9.0B | $9.8B | $10.7B | $9.9B | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B | ||
| Total Revenue | $8.4B | $9.0B | $9.8B | $10.7B | $9.9B | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $2.4B | $2.6B | $2.8B | $3.1B | $3.5B | $3.7B | $4.0B | $4.3B | $5.3B | $6.2B | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $6.0B | $6.5B | $7.0B | $7.6B | $6.4B | $8.2B | $8.7B | $9.9B | $11.5B | $13.9B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $5.5B | $5.2B | $5.5B | $6.1B | $6.5B | $7.0B | $6.7B | $7.6B | $8.9B | $10.2B | ||
| Research & Development | $920.0M | $997.0M | $1.1B | $1.2B | $1.1B | $1.2B | $1.3B | $1.4B | $1.6B | $2.1B | ||
| Research Expense | $920.0M | $997.0M | $1.1B | $1.2B | $1.1B | $1.2B | $1.3B | $1.4B | $1.6B | $2.1B | ||
| Selling, General & Administrative | $3.1B | $3.3B | $3.6B | $3.9B | $3.8B | $4.4B | $4.5B | $5.2B | $6.0B | $6.9B | ||
| General & Administrative Expenses | $3.1B | $3.3B | $3.6B | $3.9B | $3.8B | $4.4B | $4.5B | $5.2B | $6.0B | $6.9B | ||
| Salaries & Wages | $-29.0M | $-32.0M | $-21.0M | $-24.0M | $-28.0M | $-29.0M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $545.0M | $565.0M | $599.0M | $699.0M | $789.0M | $741.0M | $803.0M | $828.0M | $856.0M | $897.0M | ||
| Depreciation & Amortization | $545.0M | $565.0M | $599.0M | $699.0M | $789.0M | $741.0M | $803.0M | $828.0M | $856.0M | $897.0M | ||
| Amortization | $545.0M | $565.0M | $599.0M | $699.0M | $789.0M | $741.0M | $803.0M | $828.0M | $856.0M | $897.0M | ||
| Other Operating Expenses | $79.0M | $68.0M | $70.0M | $65.0M | $45.0M | $49.0M | $47.0M | $46.0M | $33.0M | $46.0M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $447.0M | $1.3B | $1.5B | $1.5B | $-80.0M | $1.2B | $1.6B | $2.3B | $2.6B | $3.6B | ||
| EBITDA | $1.2B | $2.0B | $2.6B | $2.2B | $1.4B | $2.5B | $2.8B | $3.4B | $3.9B | $5.1B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $233.0M | $229.0M | $241.0M | $473.0M | $361.0M | $341.0M | $470.0M | $265.0M | $305.0M | $349.0M | ||
| Intinc | -- | -- | -- | -- | -- | -- | -- | -- | $107.0M | -- | ||
| Net Non-Operating Interest Income/Expense | $-233.0M | $-229.0M | $-241.0M | $-473.0M | $-361.0M | $-341.0M | $460.0M | $-265.0M | $-305.0M | $-349.0M | ||
| Gain on Sale of Securities | $12.0M | -- | -- | -- | $363.0M | $-178.0M | -- | -- | -- | -- | ||
| Other Income/Expense | $77.0M | $48.0M | $-142.0M | $428.0M | $-2.0M | $-62.0M | $-434.0M | $116.0M | $381.0M | $64.0M | ||
| Other Special Charges | $-37.0M | $-124.0M | $156.0M | $-358.0M | $362.0M | $218.0M | $-38.0M | $-358.0M | $-321.0M | $-228.0M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $28.0M | $37.0M | $36.0M | $38.0M | $52.0M | $40.0M | $24.0M | $69.0M | $16.0M | $101.0M | ||
| Special Income Charges | $-832.0M | $-322.0M | $-139.0M | $-153.0M | $-403.0M | $-470.0M | $-197.0M | $42.0M | $-16.0M | $-295.0M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | $73.0M | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $410.0M | $1.2B | $1.7B | $1.2B | $282.0M | $1.4B | $1.6B | $2.2B | $2.6B | $3.7B | ||
| Pre-Tax Income | $177.0M | $933.0M | $1.4B | $687.0M | $-79.0M | $1.1B | $1.1B | $2.0B | $2.3B | $3.4B | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-170.0M | $828.0M | $-249.0M | $-4.0B | $2.0M | $36.0M | $443.0M | $393.0M | $436.0M | $493.0M | ||
| NET INCOME | ||||||||||||
| Net Income | $347.0M | $104.0M | $1.7B | $4.7B | $-82.0M | $1.0B | $698.0M | $1.6B | $1.9B | $2.9B | ||
| Net Income (Continuing Operations) | $347.0M | $104.0M | $1.7B | $4.7B | $-115.0M | $985.0M | $698.0M | $1.6B | $1.8B | $2.9B | ||
| Net Income (Discontinued Operations) | $347.0M | $104.0M | $1.7B | $4.7B | $-82.0M | $1.0B | $698.0M | $1.6B | $1.9B | $2.9B | ||
| Net Income (Common Stockholders) | $347.0M | $104.0M | $1.7B | $4.7B | $-115.0M | $985.0M | $642.0M | $1.6B | $1.9B | $2.9B | ||
| Normalized Income | $879.0M | $852.5M | $1.3B | $-3.1B | $727.6M | -- | -- | -- | -- | $3.7B | ||
| TOTALS | ||||||||||||
| Total Expenses | $7.9B | $7.8B | $8.3B | $9.2B | $10.0B | $10.7B | $10.6B | $11.9B | $14.1B | $16.5B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.5B | $1.5B | $1.5B | ||
| Average Shares Outstanding (Diluted) | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.5B | $1.5B | $1.5B | ||
| Shares Outstanding | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.4B | $1.5B | $1.5B | $1.5B | ||
| Basic EPS | $0.26 | $0.08 | $1.21 | $3.38 | $-0.08 | $0.69 | $0.45 | $1.08 | $1.26 | $1.96 | ||
| Basic EPS (Continuing Operations) | $0.26 | $0.08 | $1.21 | $3.38 | $-0.08 | $0.69 | $0.45 | $1.08 | $1.26 | $1.96 | ||
| Diluted EPS | $0.25 | $0.08 | $1.19 | $3.33 | $-0.08 | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 | ||
| Diluted EPS (Continuing Operations) | $0.25 | $0.08 | $1.19 | $3.33 | $-0.08 | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | -- | $33.0M | $55.0M | $55.0M | $23.0M | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | $78.0M | $-22.0M | -- | -- | -- | ||
| Minority Interests | $6.7B | $7.0B | $8.7B | $13.9B | $15.3B | -- | -- | $1.0M | $8.0M | $6.0M | ||
| Non Recurring Operation Expense | $804.0M | $285.0M | $103.0M | $115.0M | $278.0M | $430.0M | $173.0M | $-111.0M | -- | $194.0M | ||
| Other Gand A | $3.1B | $3.3B | $3.6B | $3.9B | $3.8B | $4.4B | $4.5B | $5.2B | $6.0B | $6.9B | ||
| Other Impairment Of Capital Assets | $11.0M | $4.0M | $35.0M | $105.0M | $460.0M | $370.0M | $132.0M | $58.0M | $386.0M | $46.0M | ||
| Other Write Off | -- | -- | -- | $17.0M | $27.0M | $25.0M | -- | -- | -- | -- | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | -- | $33.0M | $55.0M | $55.0M | $23.0M | -- | -- | ||
| Preferred Stock Dividends | -- | -- | -- | -- | $33.0M | $55.0M | $55.0M | $23.0M | -- | -- | ||
| Rent And Landing Fees | $80.0M | $88.0M | $92.0M | $80.0M | -- | -- | -- | -- | -- | -- | ||
| Write Down | -- | -- | -- | $-19.0M | -- | -- | -- | -- | -- | -- | ||
| Restruct | $28.0M | $37.0M | $36.0M | $38.0M | $52.0M | $40.0M | $24.0M | $69.0M | $16.0M | $101.0M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BSX | $56.91 | -1.2% | 10.03M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Boston Scientific Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW